Results 101 to 110 of about 7,202 (139)
CD30-CD30 Ligand Interaction in Primary Cutaneous CD30+T-Cell Lymphomas: A Clue to the Pathophysiology of Clinical Regression [PDF]
Blood, 1999 Primary CD30+ cutaneous T-cell lymphomas (CTCLs) represent a spectrum of non-Hodgkin’s lymphomas (NHLs) that have been well defined at the clinical, histologic, and immunologic level. This group, which includes 2 main entities (large cell lymphoma and lymphomatoid papulosis [LyP]) and borderline cases, is characterized by the expression of CD30 antigen
Maggi E
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
CD30 Ligand/CD30 Interaction Is Involved in Pathogenesis of Inflammatory Bowel Disease
Digestive Diseases and Sciences, 2012Although CD30 has long been recognized as an important marker in many lymphomas of diverse origin, and as an activation molecule on B and T cells, its primary function has remained obscure. Soluble CD30 (sCD30) is released from CD30 on the cell membrane by enzymatic cleavage.
Xun Sun +2 more
exaly +3 more sources
A Critical Role of CD30 Ligand/CD30 in Controlling Inflammatory Bowel Diseases in Mice
Gastroenterology, 2008A CD30-ligand (CD30L) is a 40-kilodalton, type II membrane-associated glycoprotein belonging to the tumor necrosis factor family. Serum levels of soluble CD30 increased in inflammatory bowel diseases (IBD), suggesting that CD30L/CD30 signaling is involved in the pathogenesis of IBD.
Xun Sun +2 more
exaly +3 more sources
Association study between CD30 and CD30 ligand genes and type 1 diabetes in the Japanese population [PDF]
Genes and Immunity, 2002 CD30-CD30 ligand (CD30L) signal transduction appears to protect against autoimmune diabetes by preventing expansion of autoreactive T cells and suppressing Th1-cytokine response. The purpose of this study was to determine whether CD30 or CD30L genes serve as a novel susceptibility gene for type 1 diabetes in humans. We screened CD30 and CD30L genes for
Kenji Ihara, Ihara K, Kohno H
exaly +3 more sources
CD30 ligand in lymphoma patients with CD30+ tumors.
Journal of Clinical Oncology, 1997PURPOSE CD30 ligand (CD30L), which is expressed on resting B and activated T lymphocytes, can induce cell death in several CD30+ cell lines. Patients with CD30+ tumors (Hodgkin's disease and Ki-1+ non-Hodgkin's lymphoma) frequently have elevated soluble CD30 (sCD30) levels in their serum, which correlates with a poor prognosis.
A, Younes +10 more
openaire +2 more sources
Regulation of murine B cell growth and differentiation by CD30 ligand
European Journal of Immunology, 1995AbstractA ligand for CD30 has been recently cloned, and has been shown to have sequence homology with the tumor necrosis factor family of cytokines. CD30 ligand (CD30L) was found to be induced on helper T cell clones, and its receptor was expressed on freshly isolated and activated murine B cells.
K H Grabstein +2 more
exaly +3 more sources
Immunology Letters, 2014
CD30 and CD30 ligand (CD30L) are members of TNF-receptor and TNF superfamilies respectively. CD30(+)T cells are increased in several diseases and interaction between CD30(+) and CD30L(+)T cells leads either to cell proliferation or apoptosis. In patients with rheumatoid arthritis (RA), soluble CD30 (sCD30) levels seem to reflect the recruitment of CD30(
Claudio Lunardi +2 more
exaly +5 more sources
CD30 and CD30 ligand (CD30L) are members of TNF-receptor and TNF superfamilies respectively. CD30(+)T cells are increased in several diseases and interaction between CD30(+) and CD30L(+)T cells leads either to cell proliferation or apoptosis. In patients with rheumatoid arthritis (RA), soluble CD30 (sCD30) levels seem to reflect the recruitment of CD30(
Claudio Lunardi +2 more
exaly +5 more sources
Reverse signaling via CD30 ligand
The Journal of Immunology, 1996Abstract CD30 ligand (CD30L), a member of the TNF family, is a type II membrane protein with a C-terminal extracellular domain that is homologous with the extracellular domains of other TNF family members. Also, like most TNF family members, the N-terminal cytoplasmic domain of CD30L is conserved across species, but not between family
S R, Wiley, R G, Goodwin, C A, Smith
openaire +2 more sources
CD30 ligand is a new therapeutic target for central nervous system autoimmunity [PDF]
Journal of Autoimmunity, 2015 The CD30 ligand (CD30L)/CD30 axis plays a critical role in Th1 and Th17 cell differentiation. However, the role in the pathogenesis of central nervous system autoimmunity remains unknown. Here we show the resistance for experimental autoimmune encephalomyelitis (EAE) with markedly reduced induction of antigen-specific Th1 and Th17 cells in CD30L ...
Jun-Ichi Kira +2 more
exaly +3 more sources
Characterisation of the human CD30 ligand gene structure
Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1997The gene for the human CD30 ligand was molecularly cloned, sequenced and characterised. The gene structure consisted of four exons and three intervening introns spaced over 17.1 kb of genomic DNA. The 5' flanking region of the CD30L gene was sequenced and analysis of the region revealed the presence of several regulatory regions including a poly-dT ...
E J, Croager, L J, Abraham
openaire +2 more sources